Foley Hoag LLP represented Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) on the transaction Dicerna signed a global licensing and research collaboration with Eli Lilly and Company focused…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
